CSL is now the local market’s 3rd largest company with a market cap of $138bn, Australia’s most successful biotech/healthcare stock remains well below its 2020 high very much in line with the majority of the growth sector following the recent rally by the global bond yields. The company has done nothing wrong but international equities have seen a revaluation of the growth names due to the mentioned rising bond yields.
- We are considering selling/reducing our position into strength, ideally back above $300.
MM is mildly bullish CSL ~$286
Add To Hit List
